Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Results Among 80 participants (mean [SD] age, lithium: 72.93 [8.77] years; placebo: 71.22 [6.47] years; 56% female), none of the 6 coprimary outcomes met the prespecified significance threshold. Hippocampal and cortical volumes showed a decline over time in both groups, but no significant treatment × time interactions.

Key findings

Why it matters

In this 80-person pilot trial, low-dose lithium did not significantly affect any of the six main outcomes, and brain volumes declined in both groups. It provides no evidence that lithium treats or prevents cognitive impairment.

Study details

How this study scored 72/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 1 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 72 of 100.72 of 100 points earned28 not earned

Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA neurology)
Journal's citation record 2 / 4 JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomised controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 170 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 1 / 2 Randomised (as stated in the record)
Times cited 3 / 7 Cited 16 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.0 citations a year over 2 year(s) since 2026
Impact for its field and year 6 / 6 Cited 75.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Meryl A. Butters: h-index 74 (OpenAlex, whole career)
Institution's track record 2 / 3 Duke University: institution h-index 1,541 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41770546)
Free to read 2 / 2 Free to read
Total 72 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Gildengers, A. G., Ibrahim, T. S., Anderson, S. J., Emanuel, J. E., Santini, T., Diaz, J. L., et al. (2026). Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial. JAMA neurology. https://doi.org/10.1001/jamaneurol.2026.0072

Vancouver

Gildengers AG, Ibrahim TS, Anderson SJ, Emanuel JE, Santini T, Diaz JL, et al. Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial. JAMA neurology. 2026. doi:10.1001/jamaneurol.2026.0072. PMID: 41770546.

BibTeX

@article{gildengers2026-41770546,
  author  = {Gildengers, A. G. and Ibrahim, T. S. and Anderson, S. J. and Emanuel, J. E. and Santini, T. and Diaz, J. L. and Lopresti, B. J. and Royse, S. K. and others},
  title   = {{Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2026},
  doi     = {10.1001/jamaneurol.2026.0072},
  pmid    = {41770546},
  url     = {https://doi.org/10.1001/jamaneurol.2026.0072}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments

Similar studies

More on Treatments

See all studies in Treatments →